RS BioTherapeutics (Convertible Notes)
Funding Details
- Awarder
- StartEngine
- Date Award
- April 24, 2024
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Premoney Valuation
- $40,000,000
- Valuation
- $40,000,000
- Funding Amount:
- $1,240,000
Company Info
- Founding Year
- Not provided
- Traction
- None
- Organizations Involved
- None
- Founders
- Dean Hart, Michelle L. Shuffett, Curtis Rhine, Justin Molignoni
- Company Description
- RS BioTherapeutics is developing a groundbreaking drug platform to address inflammatory lung diseases like Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). Their science-backed approach offers new treatment avenues not just for these respiratory diseases, but many others that could be addressed using their innovative platform.
- Market
- Respiratory Diseases
- Location
- Cumberland, MD, US
- Coinvestors
- None